Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
- Not stated
- Not stated
- Dec 5, 2024
Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.
Or read the full text and all 3 standing review criteria here, free with an account. Create free account
Summary
This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.)…
Related NIH announcements
INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
$500k
NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
The full announcement, free with an account
- The full announcement text, not just the first two sentences
- All 3 standing review criteria National Institutes of Health applies to this kind of proposal (its standard framework, not criteria written for this announcement)
On Plus, $39 a month
- The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
- Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
- A Reviewer Scorecard of your draft against these criteria
More from National Institutes of Health
NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
$500k